Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company

Ann Intern Med. 2022 Jul;175(7):1053-1055. doi: 10.7326/M22-0756. Epub 2022 Jun 21.

Authors

Hussain S Lalani¹, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliation

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

PMID: 35724381
DOI: 10.7326/M22-0756

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Aged
Cost Savings
Drug Costs
Drugs, Generic
Humans
Medicare Part D*
Prescription Drugs*
United States

Substances

Drugs, Generic
Prescription Drugs